Biogen (NASDAQ:BIIB) Stock Rating Raised to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded shares of Biogen (NASDAQ:BIIB) from a hold rating to a strong-buy rating in a report issued on Saturday morning,Wall Street Zen reports.

A number of other analysts also recently weighed in on BIIB. JPMorgan Chase & Co. upgraded Biogen from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $210.00 to $300.00 in a report on Monday, October 12th. Wedbush boosted their price objective on Biogen from $212.00 to $225.00 and gave the company a “neutral” rating in a research note on Thursday. Wells Fargo & Company upped their target price on Biogen from $250.00 to $310.00 and gave the company an “overweight” rating in a research report on Tuesday, October 20th. Needham & Company LLC upped their target price on Biogen from $256.00 to $290.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Seaport Research Partners raised Biogen to an “outperform” rating in a research note on Monday, October 12th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $251.00.

Biogen Stock Up 1.6%

Shares of NASDAQ BIIB opened at $253.62 on Friday. The company’s 50 day moving average price is $227.08 and its 200-day moving average price is $201.04. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.26 and a current ratio of 1.95. Biogen has a 52-week low of $146.52 and a 52-week high of $258.78. The company has a market capitalization of $37.49 billion, a P/E ratio of 108.38, a price-to-earnings-growth ratio of 2.97 and a beta of 0.09.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Wednesday, October 28th. The biotechnology company reported $2.62 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.63. Biogen had a net margin of 3.37% and a return on equity of 9.38%. The company had revenue of $2.80 billion during the quarter, compared to analysts’ expectations of $2.63 billion. During the same period in the prior year, the company posted $4.81 earnings per share. Biogen’s revenue for the quarter was up 10.6% compared to the same quarter last year. Equities analysts forecast that Biogen will post 12.44 earnings per share for the current year.

Institutional Investors Weigh In On Biogen

Several hedge funds and other institutional investors have recently bought and sold shares of BIIB. BlackRock Inc. purchased a new stake in shares of Biogen in the second quarter worth approximately $3,453,878,000. Primecap Management Co. CA bought a new position in shares of Biogen in the second quarter valued at approximately $3,274,304,000. Wellington Management Group LLP boosted its position in shares of Biogen by 5.3% during the second quarter. Wellington Management Group LLP now owns 3,117,469 shares of the biotechnology company’s stock valued at $673,560,000 after buying an additional 155,828 shares during the last quarter. Amundi boosted its position in shares of Biogen by 91.8% during the second quarter. Amundi now owns 1,516,831 shares of the biotechnology company’s stock valued at $327,727,000 after buying an additional 726,004 shares during the last quarter. Finally, Legal & General Group Plc purchased a new position in shares of Biogen during the second quarter valued at approximately $322,640,000. 87.93% of the stock is owned by institutional investors.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Better-than-expected Q3 results: Biogen reported adjusted earnings of $2.62 per share, above the $1.99 consensus estimate, while revenue reached $2.80 billion versus expectations of $2.63 billion. Revenue increased 10.6% year over year, supporting the view that the company is returning to growth. Biogen Reaches New 1-Year High on Better-Than-Expected Earnings
• Positive Sentiment: Analysts raised targets following the earnings beat: UBS lifted its target to $300, while Baird and Needham raised theirs to $290. Argus upgraded Biogen from “hold” to “buy” with a $280 target; RBC increased its target to $272 and retained an outperform rating. Canaccord Genuity also raised its target to $272 and assigned a buy rating. Analysts Increase Their Forecasts on Biogen After Upbeat Q3 Results
• Positive Sentiment: Growth narrative is improving: RBC analysts said Biogen’s quarterly performance suggests a growth-led comeback, potentially sustaining investor momentum after a period of declining results. Biogen Swings Back to Growth as Stock Momentum Could Continue
• Positive Sentiment: Alzheimer’s pipeline catalyst: Biogen plans to present long-term and real-world data at the November CTAD conference, including five-year Clarity AD extension data for lecanemab and additional Phase 2 CELIA data for diranersen. Positive results could strengthen confidence in the company’s Alzheimer’s portfolio and future growth prospects. Biogen to Present New Data Across Alzheimer’s Disease Portfolio at CTAD 2026
• Neutral Sentiment: Mixed analyst valuation signals: TD Cowen and Truist raised targets to $260, but those imply only modest upside from the current level. The concentration of target increases after earnings is supportive, although expectations are now higher.
• Negative Sentiment: Morgan Stanley remains cautious: The firm raised its target to $238 but kept an “equal weight” rating, indicating potential downside if Biogen’s growth recovery or pipeline data disappoints.

Biogen Company Profile

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.